Home
Search results “Adjuvant hormonal therapy in prostate cancer”
Urowebinar: Hormone therapy in prostate cancer  who, how and when
 
41:09
Presenter: Dr. Vijay Ramani Androgens promote the growth of both normal and cancerous prostate cells by binding to and activating the androgen receptor. Once activated, the androgen receptor stimulates the expression of specific genes that cause prostate cells to grow. Hormone therapy, also called androgen deprivation therapy, can block the production and use of androgens inhibiting the cell growth. Different types of androgen deprivation therapy are available in different modalities: neoadjuvant and adjuvant setting, or as a single agent therapy. How to choose the best treatment’s agent, modality and timing will be clarified in this comprehensive webinar.
Hormone Therapy For Prostate Cancer Treatment- Hormone Therapy Side Effects
 
00:42
Now we have a number of medications available as pills, injections, and implants that can give men the hormonal therapy is also sometimes given after radiotherapy (adjuvant therapy), where aim to reduce chance cancer coming back. Because of their possible side effects (including blood clots and breast enlargement), estrogens have been replaced by other types hormone therapy are you consider as a treatment for prostate cancer? Here is information about the that may experience this get better within 3 to 12 months after ends. And difficulty getting or keeping an erection. His presentation was certainly the most controversial and provocative of session. Zero the end of prostate cancer. How does hormone therapy treat prostate cancer? 4. Make sure you discuss these with your doctor or nurse before start treatment. Your doctor prostate cancer depends on the hormone testosterone in order to grow. Advantages and disadvantages of hormone therapymonitoring the effects therapymanaging side therapycomplementary alternative therapies 15 aug 2017 to minimize therapy medications, your doctor may recommend you take them only until prostate cancer responds treatment. The side effects of hormone therapy and the time it takes to get over some them depend on many factors. Hormone therapy for localised prostate cancer further detailed understanding hormone. Hormonal therapies for advanced prostate cancer information and hormone therapy harvard knowledge canada. You can also talk to our specialist nurses about side effects. Estrogens (female hormones) were once the main alternative to orchiectomy for men with advanced prostate cancer. What does hormone therapy involve? 6. Hormonal therapy can cause a range of side effects that include erection difficulties (ed), lowered sex drive, hot flushes, weight gain, breast swelling and fatigue once reserved solely as treatment for metastatic prostate cancer, hormone is now also used in variety other ways. What are the side effects of hormone therapy for prostate cancer? Loss interest in sex (lowered libido) erectile dysfunctionloss bone densityloss muscle mass and physical strengthinsulin resistance 11 mar 2016 other androgen suppressing drugs. Your doctor or clinical nurse specialist will be able to offer you advice. Typically, you can of the treatment. Hormone therapy what are the side effects? Prostate cancer effects of hormone in men how affects you. He stated that testosterone might not adding radiation therapy to hormone increases survival among men with locally advanced prostate cancer. It depends on the drug you are having and how long have been taking it. For some men, erection problems are permanent. Anti androgens can cause less sexual side effects as agonists but are not effective an orchiestomy or lhrh in treating the disease, leaving it a poor hormonal therapy is main treatment for advanced prostate cancer. We describe here the most common side effects of hormone therapy and how to manage or reduce them. Effective
Views: 284 health tips
How Is Hormone Therapy Used To Treat Prostate Cancer?
 
38:45
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Hormone therapy may be used in several ways to treat prostate cancer, including: Adjuvant hormone therapy. Hormone therapy that is given after other primary treatments to lower the risk that prostate cancer will come back is called adjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence may receive adjuvant hormone therapy after radiation therapy or prostatectomy (surgery to remove all or part of the prostate gland) (5). Factors that are used to determine the risk of prostate cancer recurrence include the tumor's grade (as measured by the Gleason score), the extent to which the tumor has spread into surrounding tissue, and whether or not tumor cells are found in nearby lymph nodes. Men who have adjuvant hormone therapy after prostatectomy live longer without having a recurrence than men who have prostatectomy alone, but they do not live longer overall (5). Men who have adjuvant hormone therapy after external beam radiation therapy for prostate cancer live longer, both overall and without having a recurrence, than men who are treated with radiation therapy alone (5, 6). Neoadjuvant hormone therapy. Hormone therapy given before other treatments is called neoadjuvant hormone therapy. Men with early-stage prostate cancer that has an intermediate or high risk of recurrence often receive hormone therapy before or during radiation therapy, in addition to receiving hormone therapy after radiation therapy. Men who receive hormone therapy in combination with radiation therapy live longer overall than men who receive radiation therapy alone (7). The use of neoadjuvant hormone therapy (alone or in combination with chemotherapy) before prostatectomy has not been shown to prolong survival and is not a standard treatment. Hormone therapy alone. Hormone therapy is sometimes used alone for palliation or prevention of local symptoms in men with localized prostate cancer who are not candidates for surgery or radiation therapy (8). Such men include those with a limited life expectancy, those with advanced local tumor stage, and/or those with other serious health conditions. Hormone therapy used alone is also the standard treatment for men who have a prostate cancer recurrence documented by CT, MRI, or bone scan after treatment with radiation therapy or prostatectomy. Hormone therapy is often recommended for men who have a "biochemical" recurrence—a rapid rise in prostate-specific antigen (PSA) level—especially if the PSA level doubles in fewer than 12 months. However, a rapid rise in PSA level does not necessarily mean that the prostate cancer itself has recurred. The use of hormone therapy in the case of a biochemical recurrence is somewhat controversial. Finally, hormone therapy used alone is also the standard treatment for men who are found to have metastatic disease (i.e., disease that has spread to other parts of the body) when their prostate cancer is first diagnosed (9). Whether hormone therapy prolongs the survival of men who have been newly diagnosed with advanced disease but do not yet have symptoms is not clear (10, 11). Moreover, because hormone therapy can have substantial side effects (see Question 6), some men prefer not to take hormone therapy before symptoms develop. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 294 Martina Santiago
Hormone deprivation  for prostate cancer is dangerous. Avoid it!
 
21:50
Hormone deprivation for prostate cancer is dangerous. Avoid it There is a common misunderstanding on the role of hormones in cancer. Here are some simple rules. 1. Tumor inherits its hormone dependence from the organ where it was formed. Like breast tumor responds to breast hormones like estrogen. 2. Hormones are not carcinogens and do not initiate cancer. They merely accelerate tumor growth, which is known as tumor promotion 2a.Carcinogens initiate a tumor by transforming a normal cell into a malignant. Hormones do not transform cells. They merely promote the growth of transformed cells. 2b. Hormone depletion does not cure cancer. It retards tumor growth and may induce tumor dormancy. 3. As cancer progresses, tumor dependency on hormones declines 3a. This tumor property is known as de-differentiation, which makes tumor independent from hormones. Anti-hormones do not cure cancer, but they may induce tumor dormancy. Unfortunately oncology ignores these rules. Many healthy men carry dormant tumors in their prostates Current treatments, like androgen deprivation, radiation and surgery do not cure cancer. They cannot prevent cancer recurrence and their harm outweighs their benefit. When tumor is confined to the prostate brachytherapy is the treatment of choice. decades. Every second male older than 60 years carries in his prostate a dormant tumor. How did he do it and what is his secret? This capability exists in every male even if he got clinical cancer. It is our duty to harness it during therapy. .
Views: 3825 Gershom Zajicek M.D,
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Views: 24026 charlottecancer
Adjuvant or Salvage RT Post Radical Prostatectomy
 
25:08
Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature comparing the advantages and disadvantages of adjuvant and salvage radiation therapy (RT) for biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.
Hormonal Therapy and Prostate Cancer
 
02:23
Dr. Matthew Cooney discusses how hormone therapy is used for prostate cancer and how to minimize treatment side effects. http://prostatecancerletter.com/
Views: 151 Matthew Cooney
ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review
 
05:49
Dr Vale talks to ecancertv at ECC 2015 about the results of a systematic review and meta-analysis that examined the role of combining docetaxel or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer. She notes that slightly different conclusions were drawn for metastatic and non-metastatic disease. Adding docetaxel to ADT not only improved patients overall survival (OS) but also reduced the failure rate in metastatic disease. In the non-metastatic setting, failure-free survival was again improved with the chemotherapy but no clear OS benefit was seen. Bisphosphonates had a moderate benefit in the metastatic setting but there was no evidence of any benefit in non-metastatic disease. ecancer's filming at ECC 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Views: 74 ecancer
Hormone Treatment
 
03:19
Hormone treatments can help men with advanced prostate cancer.
Hormone Therapy for Breast Cancer and the Side Effects of Tamoxifen
 
03:42
Dr. VK Gadi discusses breast cancer treatment with hormone therapy and the side effects associated with the use of Tamoxifen. Learn more about breast cancer: http://ow.ly/yC1S3092JIW Subscribe to our channel: http://ow.ly/cw9B308MFsc
When Should I Stop Anti-Hormone Therapy?
 
03:18
Find out more about Breast Cancer Index (BCI): http://www.breastcanceranswers.com/breastcancerindex/ When should you stop taking Anti-Hormone Therapy treatment for you breast cancer? Find out from Dr. Jay Harness in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Prostate Cancer: PSA After Surgery
 
04:15
How necessary is the PSA blood test after treatment of prostate cancer? Why do some PSA levels fluctuate after surgery? Listen to Dr. Hafron explain in this clip from our April Prostate Cancer Survivorship Series.
Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer
 
08:50
Prof James (University of Warwick, Warwick, UK) and Prof Efstathiou (MD Anderson Cancer Center, Houston, USA) discuss survival results from the STAMPEDE randomised controlled trial for ecancertv at ASCO GU 2016. Celecoxib was investigated with or without zoledronic acid for hormone-naïve prostate cancer. The data showed no survival advantage for the addition of celecoxib alone for men starting long-term hormone therapy for the first time. However, the addition of celecoxib combined with zoledronic acid demonstrated a survival advantage for men with metastatic disease, in a pre-planned analysis, and requires further investigation. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Views: 251 ecancer
Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?
 
05:47
Dr Mohammad Parvez Shaikh, (Loyola University Medical Centre, Maywood, USA) talks to ecancertv at ASCO GU 2015 about cancer management after radical prostatectomy. He discusses his meta-analysis on the difference between early adjuvant radiotherapy versus watchful waiting management strategies.
Views: 1454 ecancer
Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer
 
07:13
Dr Ahlgen speaks with ecancertv at ASCO 2016 about the results of SPCG12, a randomised phase III trial assessing patient survival following radical prostatectomy with docetaxel. Docetaxel has previously proved to efficacious in prolonging survival in advanced castrate resistant prostate cancer (PCa), but Dr Ahlgren reports that, in Kaplan-Meier analysis, there was no significant difference between patients receiving docetaxel after prostatectomy or those receiving surveillance and care. He highlights that docetaxel as a monotherapy seems to generate a more rapid biochemical progression in a subgroup of patients, and that further analysis of this subgroup is warranted.
Views: 65 ecancer
How long does chemotherapy or hormone therapy for prostate cancer last? (Kathryn Bylow, MD)
 
00:41
Kathryn Bylow, MD, hematologist/oncologist, talks about the average length of chemotherapy and hormone therapy treatment for prostate cancer. She also explains the factors that can make the therapy take less time or make it take longer. Dr. Bylow is part of the Froedtert & the Medical College of Wisconsin Prostate and Urologic Cancer Program in Milwaukee, Wis. http://www.froedtert.com/prostate-cancer
Radiation Therapy Side Effects for Prostate Cancer Patients
 
06:32
Michael Steinberg, M.D. - UCLA educates patients on the side effects of radiation therapy.
Hormonal Therapy for Breast Cancer by Lange Productions
 
00:47
Hormonal Therapy for breast cancer by Lange Productions
Views: 666 LangeProductions
Key Developments in Non-Metastatic & Metastatic Hormone-Sensitive Prostate Cancer
 
22:36
The group discuss a series of phase II trials, predictive biomarkers and signpost emerging therapies from the congress. The discussion begins with reference to a Scandinavian adjuvant study (SPCG-13). Which was a randomised phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer. The group comments that the trial was negative and did not improve BDFS. The panel also highlight the continued data from LATITUDE where a detailed analyses was discussed by our panel with the key conclusions that adding AA + P to ADT delays the need for subsequent PC therapy vs ADT for pts with NDx-HR mCNPC. Time to subsequent therapy, life-prolonging therapy, and chemo strongly favoured AA + P, even though most pts receiving PBOs remaining on treatment had crossed over to AA + P or other life-prolonging subsequent therapy. The theme of ASCO was precision medicine and the group close the discussions with the PROPHECY trial. A multicentre prospective trial of circulating tumour cells (CTC) AR-V7 detection in men with mCRPC receiving abiraterone or enzalutamide. Finally the group remark on Study 8 (olaparib & abiraterone trial) and the KEYNOTE-199 (pembrolizumab for docetaxel-refractory mCRPC) and highlight that we will need to wait for further data to emerge on both PARPi and Immunotherapies.
Views: 28 ecancer
Intermittent Hormone Therapy for Rising PSA:  Is it a Good Option?
 
02:36
When the PSA begins to rise after surgery or radiation, many men are told to begin hormone therapy. Some studies suggested that the hormones could be used intermittently rather than continuously. Now a well done study provides important new information for men faced with this problem as discussed in the video.
Views: 947 Gerald Chodak MD
Docetaxil in hormone therapy improves survival in metastatic, hormone-sensitive prostate cancer
 
07:53
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.
Views: 345 ecancer
PSA Levels After Prostate Cancer Treatment
 
04:03
Dr. Tutrone explains how different types of treatment require different PSA levels to be considered cured, as well as how long PSA levels have to be monitored for recurrence of prostate cancer. LAST WEEK'S VIDEO - Prostatectomy Recovery Explained http://youtu.be/hDc5sBUxejY SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING PROSTATE CANCER NEWS http://www.youtube.com/subscription_center?add_user=ProstateCancerLive VISIT PROSTATECANCERLIVE.com FOR TONS OF INFORMATIVE VIDEOS http://www.prostatecancerlive.com/# SUGGEST THE NEXT TOPIC FOR OUR PROSTATE CANCER EXPERTS! http://www.prostatecancerlive.com/# CONNECT WITH US! Google+: http://bit.ly/17F4WQr Facebook: https://www.facebook.com/pages/Prostate-Cancer-Live/107234326132305 Twitter: https://twitter.com/ProstateLive ______ Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Views: 17326 Prostate Cancer Live
Chemohormonal therapy for hormone-sensitive newly metastatic prostate cancer
 
05:18
Ten years after pivotal results of docetaxel in castration-resistant prostate cancer, J.Bellmunt discusses results of chemohormonal therapy in patients with hormone-sensitive, newly diagnosed metastatic prostate cancer, noting how rare such magnitude of effect is seen in oncology. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Prostate cancer hormone treatment heart risks | Dana-Farber Cancer Institute
 
02:31
Recent studies had suggested that hormone-blocking therapy for prostate cancer could raise the risk of fatal heart attacks. Paul Nguyen, MD and Toni Choueiri, MD, discuss their findings that androgen deprivation therapy (ADT) makes no difference to the rate of cardiovascular deaths in men receiving ADT compared with those who didn't. There is still a question of whether ADT elevates the risk of fatal heart attacks in patients with a history of heart disease. Read more: http://www.dana-farber.org/Newsroom/News-Releases/New-study-reassures-on-heart-risks-of-prostate-cancer-treatment.aspx
Surgery Versus Radiation in Prostate Cancer
 
02:00
Richard G. Stock, a radiation oncologist with Mount Sinai Hospital, says prostate cancer surgery isn't your typical type of cancer resection. Because the prostate's location and proximity to blood vessels and nerves, it's very difficult for surgeons to remove the prostate tumor and get a clean margin around the tissue, he says. "There are some limitations from a cancer standpoint," he says. "And many patients who have surgery may have microscopic disease left behind and may require adjuvant treatment such as hormone therapy or external beam radiation therapy afterward." Surgery has its side effects, he says, including possible incontinence and sexual dysfunction. Radiation is less invasive, however, it has its own side effects.
Views: 1620 curetoday
Long-Term Results of Post-Prostatectomy Radiotherapy
 
01:25
Douglas M. Dahl, MD, FACS, discusses the long-term results of post-prostatectomy radiotherapy.
Views: 639 Targeted Oncology
Hormonal Therapy for Breast Cancer
 
02:27
Post-surgical treatment depends on the type and stage of breast cancer. Hormonal therapy is very effective against cancer cells with estrogen and progesterone receptors.
Views: 3405 Everyday Health
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer
 
01:32
Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses a results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Views: 258 OncLiveTV
Dr. Matthew Ellis on hormonal therapy before breast cancer surgery
 
13:02
Dr. Matthew Ellis describes studies examining hormonal treatments given before breast cancer surgery and more.
Views: 1070 curetoday
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Views: 292 OncLiveTV
Post Prostatectomy Radiation
 
31:16
Dr. Patrick W. McLaughlin presented "Post Prostatectomy Radiation" at the 22nd Annual Scottsdale Prostate Cancer Symposium on Saturday, March 18, 2017.
First effective adjuvant chemotherapy for high-risk, localised prostate cancer
 
03:45
Visit http://www.ecancer.org for more Prof Sandler (Cedars Sinai Medical Center, Los Angeles, USA) presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
Views: 77 ecancer
ESTRO 2010: Radiation treatment of prostate cancer
 
13:03
Dr Jereczek-Fossa speaks about the use of radiotherapy to treat prostate cancer, the importance of image guidance and the role it plays in adjuvant post operative treatment. Dr Jereczek-Fossa also explains the choice patients face whether to have robotic surgery or image guided radiotherapy, considers the option of adjuvant surgery after radiotherapy and discusses the benefits of anti-androgen hormone therapy that have been revealed in recent clinical trials. Dr Barbara Jereczek-Fossa of the European Institute of Oncology in Milan, Italy, speaking to ecancer.tv at the European Society for Therapeutic Radiology and Oncology meeting (ESTRO 29), in Barcelona.
Views: 764 ecancer
Docetaxel + hormone & radiation therapy, for high-risk prostate cancer.
 
04:30
Chicago ASCO Annual Meeting 2015: Press Briefing Progress Against Rare and Common Cancers: Saturday, May 30 - Howard M. Sandler, Chen Hu, Seth A. Rosenthal, et al. A phase III study of adjuvant docetaxel chemotherapy, added to standard hormone and radiation therapy, for men with localized, high-risk prostate cancer. More info: http://oncoletter.ch
Views: 369 oncoletter
What is the difference between chemo and hormonal therapy? (John Charlson, MD)
 
01:15
John Charlson, MD, Medical College of Wisconsin medical oncologist, answers the question: "What is the difference between chemo and hormonal therapy?"
Hormone Therapy for breast cancer
 
03:26
New Zealand women talk about their experiences of hormone therapy for breast cancer. Breast Cancer Aotearoa Coalition (New Zealand) http://www.breastcancer.org.nz/
Views: 1543 nzbreastcancer
Prostate Cancer and Chemotherapy Treatment
 
04:09
A brief discussion of prostate cancer and the treatment of prostate cancer using chemotherapy.
Views: 265 Zackary Reynolds
Prostate Cancer: Radiation After Radical Prostatectomy- Is it Worthwhile?
 
05:30
The results of a large randomized study have been re-analyzed with new findings. Find out the results and their significance.
Views: 7089 Gerald Chodak MD
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
 
07:25
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Views: 610 OncLiveTV
How Do Hormones Treat Cancer?
 
00:46
Hormone therapies for breast cancer treatment hormonal therapy treating hormone health encyclopedia and webmd. Hormone therapy cancer research uk. Analogs of gonadotropin releasing hormone (gnrh) can be used to induce a chemical castration, that is. At cancer treatment centers of america (ctca), we may hormonal therapies do have side this is also associated with how can hormones affect the growth breast cancer? Hormones like therapy be called anti hormone. Hormone therapy on its own won't cure your prostate hormonal in oncology is hormone for cancer and one of the major modalities it was formerly used breast treatment, but has since been replaced by more selective aromatase inhibitors. Having the right information will help you make decision for if testosterone is taken away, cancer usually shrink, even it has spread to other parts of your body. Hormonal therapy hematology & medical oncology cancer hormone national breast foundationoncolink. Hormone therapy can learn how hormone therapies slow or stop the growth of for breast cancer treatment is different than menopausal 14 feb 2017 hormonal medicines treat receptor positive cancers hrt contains estrogen and contain progesterone other in cases, hormones kill cells, make cells grow more slowly, them from growing. Hormone therapy as a cancer treatment may 10 apr 2015 tamoxifen and breast prevention; Can other drugs prevent common hormone for include but even in cases where removing or killing the isn't possible, can help slow down growth. Think of it as the 4 apr 2016 meanwhile, research is ongoing to study potential efficacy hormonal manipulation in treating other cancer types. Hormone therapy what are the side effects? Prostate cancer breast treatment hormone is hormonal for cancer? Hormonal early stage receptor. Hormone therapy cancer treatment centers of america. Hormone therapy for cancer national institute. Hormonal therapies treating breast cancer macmillan hormone therapy hormonal (oncology) wikipedia. Hormone therapy for breast cancer american society. Hormone treatment fights prostate cancer webmd. Hormone therapy cancer research ukcancer uk. Though it isn't a cure, hormone are you consider therapy as treatment for prostate cancer? Exercise is probably the best thing man can do to prevent many of these side effects oestrogen play part in stimulating some breast cancers grow, there number different therapies that work 20 jul 2016 hormonal medicines whole body receptor positive cancerslowering amount estrogen or blocking its also reduce risk an early stage, 16 feb adjuvant given after surgery, chemotherapy, and therapy, likely effects, how long will last, your doctors may tell options. Cancers that can be hormone sensitive include 18 aug 2016 therapy also used to treat cancer has come back after about 2 out of 3 breast cancers are receptor positive 29 apr 2015 is prostate and use the side effects you have will depend on type prevent cells from getting hormones they need grow. Hormone therapy changes hormone levels in the body and can stop or slow down doctors use it to treat some cancers such as breast prostate cancer is a treatment that uses medicines block lower does not work for all.
Views: 48 Pan Pan 3
How are side effects from chemo and hormonal therapy managed? (John Charlson, MD)
 
01:52
John Charlson, MD, Medical College of Wisconsin medical oncologist, answers the question: "How are side effects from chemo and hormonal therapy managed?"
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Radiotherapy High Dosage Treatment 1945 US Public Health Service, Nurse Education
 
16:21
more at http://scitech.quickfound.net 'Nuclear medicine; radiation therapy; Doctor performing an in-office biopsy on a patient under local anesthesia; patient's condition is diagnosed as carcinoma of the tongue and prescribes x-ray treatments; x-ray technician figures dosage; discussion of electric voltage and amperage and how it relates to x-rays; diagrams of the penetration of x-rays into the body; animation of the destruction of cancer cells by x-rays; use of radon's seeds: these are tiny hollow metal capsules that contain radon gas. the seeds are implanted in the body inside a tumor. a nurse handles them behind a small lead shield...' Public domain film from the Prelinger Archives, slightly cropped to remove uneven edges, with the aspect ratio corrected, and mild video noise reduction applied. The soundtrack was also processed with volume normalization, noise reduction, clipping reduction, and/or equalization (the resulting sound, though not perfect, is far less noisy than the original). http://creativecommons.org/licenses/by-sa/3.0/ http://en.wikipedia.org/wiki/Radiation_therapy Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor (for example, early stages of breast cancer). Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology that focuses on radiotherapy is called radiation oncology. Radiation therapy is commonly applied to the cancerous tumor because of its ability to control cell growth. Ionizing radiation works by damaging the DNA of cancerous tissue leading to cellular death. To spare normal tissues (such as skin or organs which radiation must pass through to treat the tumor), shaped radiation beams are aimed from several angles of exposure to intersect at the tumor, providing a much larger absorbed dose there than in the surrounding, healthy tissue. Besides the tumour itself, the radiation fields may also include the draining lymph nodes if they are clinically or radiologically involved with tumor, or if there is thought to be a risk of subclinical malignant spread. It is necessary to include a margin of normal tissue around the tumor to allow for uncertainties in daily set-up and internal tumor motion. These uncertainties can be caused by internal movement (for example, respiration and bladder filling) and movement of external skin marks relative to the tumor position. Radiation oncology is the medical specialty concerned with prescribing radiation, and is distinct from radiology, the use of radiation in medical imaging and diagnosis. Radiation may be prescribed by a radiation oncologist with intent to cure ("curative") or for adjuvant therapy. It may also be used as palliative treatment (where cure is not possible and the aim is for local disease control or symptomatic relief) or as therapeutic treatment (where the therapy has survival benefit and it can be curative). It is also common to combine radiation therapy with surgery, chemotherapy, hormone therapy, immunotherapy or some mixture of the four. Most common cancer types can be treated with radiation therapy in some way. The precise treatment intent (curative, adjuvant, neoadjuvant, therapeutic, or palliative) will depend on the tumor type, location, and stage, as well as the general health of the patient. Total body irradiation (TBI) is a radiation therapy technique used to prepare the body to receive a bone marrow transplant. Brachytherapy, in which a radiation source is placed inside or next to the area requiring treatment, is another form of radiation therapy that minimizes exposure to healthy tissue during procedures to treat cancers of the breast, prostate and other organs. Radiation therapy has several applications in non-malignant conditions, such as the treatment of trigeminal neuralgia, acoustic neuromas, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, and prevention of keloid scar growth, vascular restenosis, and heterotopic ossification. The use of radiation therapy in non-malignant conditions is limited partly by worries about the risk of radiation-induced cancers...
Views: 6682 Jeff Quitney
Dr. Sweeney on Chemotherapy in Prostate Cancer
 
01:09
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.
Views: 102 OncLiveTV
Men with cancer live for 25% longer if given a drug early
 
07:07
Giving men with advanced prostate cancer a cheap chemotherapy drug soon after they are diagnosed dramatically improves survival chances, a major study has found.British researchers showed men with the cancer live 25 per cent longer if given docetaxel – an established chemotherapy drug – early on in their treatment.Up to 10,000 men with prostate cancer could benefit from the findings every year, giving them vital extra time with loved ones.At the moment prostate patients are usually only given docetaxel after standard hormone therapy has failed.But the new research, led by experts at Birmingham University, suggests giving chemotherapy at the same time as hormones is hugely beneficial.The Daily Mail launched a campaign to end needless prostate deaths almost 20 years ago, calling for earlier diagnosis and better treatments.However, last week official figures revealed that prostate cancer has now become a bigger killer than breast cancer for the first time.More than 11,800 men are now killed by the disease in Britain every year, compared with 11,400 women dying of breast cancer.Yet over the last 15 years prostate cancer has received less than half the research funding.Researchers have been trying for decades to find new and better drugs for prostate cancer.But the latest findings suggest simply giving proven treatments earlier on can make a big difference.In the past chemotherapy has been reserved for use after hormone therapy, largely to spare men the side effects of the treatment.But the researchers found giving the combination early on actually improved quality of life and reduced side effects in the long term.It cut the chance of the disease coming back by 40 per cent, slashed the risk of side effects such as broken bones or spinal compression, and saved the NHS money.The scientists, who have tracked 9,000 men with prostate cancer since 2005, also found giving men docetaxel early on boosts survival by about 10 months – an additional quarter on top of the three years men would expect to live after receiving hormone therapy alone.Study leader Professor Nick James, who will present his findings at the 2018 Genitourinary Cancers Symposium in San Francisco this weekend, said the additional life expectancy of chemotherapy makes any additional side effects worthwhile.‘How does one measure wanting to live a few more months to see a grandchild born even if the therapy results in difficult side-effects? ‘Although there is a concern about side-effects, primarily nausea and fatigue, it is clear that avoiding or delaying recurrence outweighs the upfront toxicity of chemotherapy and adds enough to overall quality of life so that using docetaxel is beneficial.’ 'I was in and out of hospital in a day'  Graham Otway is happy he is still alive to celebrate his 65th birthday next month after keyhole surgery stopped his prostate cancer in its tracks.He had suffered pain while urinating for months before a friend in the pub urged him to take a prostate-specific anti
Views: 19 Breaking News 2018
New Research on Endocrine Therapy and Breast Cancer
 
02:28
Update from the 2017 San Antonio Breast Cancer Symposium, featuring RISE Advocate Michelle Hille and Dr. Jenny Chang.